Your gateway to the world of medicine
Cancer News
About Us
Health Professionals
Patients and public
Contact Us

Updates in oncology

MedicineWorld.Org: Updates in oncology

Lung cancer main Lung cancer news Main cancer news  

Alimta for the treatment of non-small cell lung cancer
  • See JCO May 1, 2004 for more details
  • FDA has approved Alimta for second line treatment of non-small cell lung cancer
  • Dosage: 500 mg/m2 as 10 minute iv infusion day 1 of a q 21 day cycle. Repeat until disease progression.
  • Response rate: 9.1%, median progression free survival 2.9 months, median survival 8.3 months.
  • Side effects: Less severe compared to taxotere, less neutropenia compared to docetaxel. Other side effects: fatigue (40%), nausia (33%), vomiting(17%), stomatitis (15%), neurosensory, alopecia (6%), diarrhea (13%), rash (15%), edema (5%)

  • Precautions
  • Monitor creatinine clearance and hold if <40
  • Start B12 and folate supplimentation one week prior to starting treatment and continue throughout treatment
  • Use steroid prophylaxis to decrease the incidence of skin rash. The dose is 4 mg bid for 3 days(one day before, on the day of chemo, and one day after chemo).

MedicineWorl.Org: Updates in oncology

Home| Breast cancer news | Common terms| Breast cancer treatment| Treatment by stage| Surgical treatment| Chemotherapy| Chemo drugs| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy| Radiation therapy| Monoclonal therapy| High dose chemotherapy| Recurrent breast cancer| Bisphosphonates | Pregnancy and breast cancer | Risk factors | Risk details | My risk | Comprehensive | Breast cancer statistics | African Americans | Ashkenazi | Asians | Hispanic | Men | Native Americans | Older women | Younger women | Pregnant women | BRCA

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.